StemCell Therapy

A qualitative research study accomplished by HTF MI titled Global Connective Tissue Growth Factor Market covers detailed Product / Industry Scope, current and future market size scenario and elaborates outlook and status to 2025 provides primary data, studies and vendor briefings. The market Study is segmented by key regions along with country level break-up which is accelerating the marketization and by products type, application/end-users. The research study provides estimates for Connective Tissue Growth Factor forecast till 2025. Some of the Major Players Included in the study are BLR-200, IB-DMD, OLX-201, PBI-4050, Others, Demand Coverage (Market Size & Forecast, Consumer Distribution):, Hypertrophic Scars, Opthalmology, Genetic Disorders, Liver Fibrosis, Others, BLR Bio LLC, FibroGen Inc, ProMetic Life Sciences Inc, RXi Pharmaceuticals Corp, North America, Europe, Asia-Pacific, South America & Middle East & Africa.

Get Free Sample Report + All Related Graphs & Charts @:https://www.htfmarketreport.com/sample-report/2214003-global-connective-tissue-growth-factor-market-study-2016-2026-by-segment

1) Can we add or profile new players as per our need?

Yes, we can add or profile new company as per client need in the report. Final confirmation to be provided by research team depending upon the difficulty of survey.

** Data availability will be confirmed by research in case of privately held company. Up to 3 players can be added at no added cost.

2) Can inclusion of additional Segmentation / Market breakdown is possible?Yes, inclusion of additional segmentation / Market breakdown is possible subject to data availability and difficulty of survey. However a detailed requirement needs to be shared with our research before giving final confirmation to client.

** Depending upon the requirement the deliverable time and quote will vary.

3) HowResearch Report is an Interesting One?

This report covers the current scenario and growth prospects of Global Connective Tissue Growth Factor for the period 2019 2025. The study is a professional and in-depth study with around n- no. of tables and figures which provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the domain.

The titled segments and sub-section of the market are illuminated below:

The Global Connective Tissue Growth Factor market has been divided into, application, type and region.

On The Basis Of Type, Market is segmented by , by Application it includes

Some of the Key Players Identified are BLR-200, IB-DMD, OLX-201, PBI-4050, Others, Demand Coverage (Market Size & Forecast, Consumer Distribution):, Hypertrophic Scars, Opthalmology, Genetic Disorders, Liver Fibrosis, Others, BLR Bio LLC, FibroGen Inc, ProMetic Life Sciences Inc, RXi Pharmaceuticals Corp, North America, Europe, Asia-Pacific, South America & Middle East & Africa

Geographic Segmentation includes North America, Europe, Asia-Pacific etc

***Sub Regions Included: North America [United States, Canada, Mexico], Asia-Pacific [China, India, Japan, South Korea, Australia, Indonesia, Malaysia, Philippines, Thailand, Vietnam], Europe [Germany, France, UK, Italy, Russia, Rest of Europe], South America [Brazil, Argentina, Rest of South America], Middle East & Africa [GCC Countries, Turkey, Egypt, South Africa, Rest of Middle East & Africa]

*** Unless until specified in Original TOC

To know more about the table of contents, you can click @https://www.htfmarketreport.com/reports/2214003-global-connective-tissue-growth-factor-market-study-2016-2026-by-segment

Furthermore, the years considered for the study are as follows:Historical year 2013-2018Base year 2018Forecast period** 2019 to 2025 [** unless otherwise stated]

**Moreover, it will also include the opportunities available in micro markets for stakeholders to invest, detailed analysis of competitive landscape and product services of key players.

Major Key Features Covered in Global Connective Tissue Growth Factor Market Report:

* To gain insightful analyses of the market and have comprehensive understanding of the Global Connective Tissue Growth Factor and its commercial landscape.* Assess the Connective Tissue Growth Factor production processes, major issues, and solutions to mitigate the development risk.* To understand the most affecting driving and restraining forces in the Connective Tissue Growth Factor and its impact in the global market.* Learn about the market strategies that are being adopted by leading respective organizations.* To understand the future outlook and prospects for Connective Tissue Growth Factor Market.

Buy this research report @https://www.htfmarketreport.com/buy-now?format=1&report=2214003

Queries we have tried to answered in Global Connective Tissue Growth Factor Market Study:Who are the Leading key players and what are their Key Business strategies in the Global Connective Tissue Growth Factor?What are the key consequences of the five forces analysis of the Connective Tissue Growth Factor?What are different opportunities and threats faced by the dealers in the Global Connective Tissue Growth Factor?What are the strengths and weaknesses and business strategies of the key vendors?

Some Extracts from Table of Contents:Chapter 1. Market OverviewChapter 3. Market DynamicsChapter 4. Research MethodologyChapter 5. Market Factor AnalysisChapter 6. Global Connective Tissue Growth Factor Market, By Delivery ModeChapter 7. Global Connective Tissue Growth Factor Market, By ApplicationChapter 8. Global Connective Tissue Growth Factor Market, By RegionChapter 9. Global Connective Tissue Growth Factor Market, By TypeChapter 10. Company LandscapeChapter 11. Company ProfilesChapter 12. Appendix

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact US :Craig Francis (PR & Marketing Manager)HTF Market Intelligence Consulting Private LimitedUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218[emailprotected]

Connect with us atLinkedIn|Facebook|Twitter

Excerpt from:
Connective Tissue Growth Factor Market outlook & growth prediction by players (Genetic Disorders , Liver Fibrosis , Others, BLR Bio LLC ) -...

When astronaut Michael Barratt returned to Earth in October 2009, he revealed that something strange had happened during his eight months in microgravity on board the International Space Station: His vision had changed.

Before his sojourn above the Earth, Barratt needed glasses to see at a distance. But once he returned from his mission in space, the astronaut also needed reading glasses to see up-close.

Barratts curious case, as well as reports of similar changes from several other astronauts, launched a series of studies on the effects of spaceflight on vision. If humans are to spend any significant time in space, scientists need to know how time spent in the microgravity environment may alter our eyes and if the changes are permanent.

The cause of the changes Barratt experienced are still unclear, but scientists hypothesize that increased pressure caused by fluid going into astronauts heads as a result of being suspended in a microgravity environment could be reshaping their optic nerve changing the structure of their eyes.

In a study published this week in the journal JAMA Opthalmology, scientists recreated the weightlessness experienced by astronauts in space on 11 people here on Earth in an effort to better understand what effect the environment has on vision. The findings may help develop countermeasures to mitigate the effects of spaceflight on astronauts eyes better preparing them for longer flights in space.

The participants were kept on bedrest for 30 days, with their heads tilted down a state supposed to simulate the physiological effects of weightlessness in space. Any changes to their optical nerves observed over the course of the study were compared with data collected from 20 astronauts who had spent around 30 days in space from the years 2012 to 2018.

Over the 30-day period, the participants developed significant swelling of their optic nerve at the back of the eye due to a buildup of fluid around the brain. Although the effects were not entirely parallel with those seen in the astronauts, the differences between the two data sets may still provide insight on the phenomenon.

Contrary to past theories, the results suggest that increased intracranial pressure, or increased pressure around the brain, as a result of fluid build-up may not be the only cause of vision changes among astronauts. In fact, the Earth-bound participants intracranial pressure levels decreased with increased weightlessness.

The results also run contrary to the theory that gender may play a role in changes to vision during spaceflight. In one of the initial studies conducted between 2012 and 2018, NASA noted that half of the astronauts onboard the International Space Station had experienced changes in vision, but none of the female astronauts had developed the same symptoms.

This study, by contrast, involved six men and five women, and the female participants also experienced swelling of their retinas.

The study also found that participants developed more severe symptoms on their right eye versus their left. This reflects the earlier results obtained from the astronauts data, suggesting that there may be asymmetry in how each eye is affected.

The results dont answer the question of how long these effects may last. In Barratts case, he reported that his right eye was permanently altered by his time in space, while his left eye returned to its pre-space condition suggesting some of the effects of weightlessness on the body may remain for years after astronauts come back down to Earth.

Read this article:
Scientists reveal what life in space does to your eyes - Inverse

Global Absorbable and Non-Absorbable Sutures Market Report 2019 Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Absorbable and Non-Absorbable Sutures industry.

The report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2574402&source=atm

For competitor segment, the report includes global key players of Absorbable and Non-Absorbable Sutures as well as some small players.

B. Braun Melsungen AGEthiconSmith & NephewDemetech CorporationConmed CorporationW.L. Gore & AssociatesTephaMeta BiomedZimmer BiometCP MedicalMiltex (A Integra LifeSciences Corporation Company)Assut Medical SarlDyNek PtyFootbergStoeltingUnimed Medical IndustriesTeleflex IncorporatedBoston Scientific CorporationMedtronicSurgical Specialties Corporation

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeAbsorbable SuturesNon-Absorbable Sutures

Segment by ApplicationCardiovascularOrthopedicGynecologyOpthalmologyGeneral SurgeryOthers

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2574402&source=atm

Important Key questions answered in Absorbable and Non-Absorbable Sutures market report:

What will the market growth rate, Overview, and Analysis by Type of Absorbable and Non-Absorbable Sutures in 2024?

What are the key factors affecting market dynamics? What are the drivers, challenges, and business risks in Absorbable and Non-Absorbable Sutures market?

What is Dynamics, This Overview Includes Analysis of Scope and price analysis of top Manufacturers Profiles?

Who Are Opportunities, Risk and Driving Force of Absorbable and Non-Absorbable Sutures market? Knows Upstream Raw Materials Sourcing and Downstream Buyers.

Who are the key manufacturers in space? Business Overview by Type, Applications, Gross Margin, and Market Share

What are the opportunities and threats faced by manufacturers in the global market?

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2574402&licType=S&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Absorbable and Non-Absorbable Sutures product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Absorbable and Non-Absorbable Sutures , with price, sales, revenue and global market share of Absorbable and Non-Absorbable Sutures in 2019 and 2015.

Chapter 3, the Absorbable and Non-Absorbable Sutures competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Absorbable and Non-Absorbable Sutures breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2019 to 2025.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2019 to 2025.

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2019 to 2025.

Chapter 12, Absorbable and Non-Absorbable Sutures market forecast, by regions, type and application, with sales and revenue, from 2019 to 2025.

Chapter 13, 14 and 15, to describe Absorbable and Non-Absorbable Sutures sales channel, distributors, customers, research findings and conclusion, appendix and data source.

This post was originally published on Market Reports Observer

Read more:
Absorbable and Non-Absorbable Sutures Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 - Market Reports Observer

New Report on Absorbable and Non-Absorbable Sutures Market size | Industry Segment by Applications (Cardiovascular, Orthopedic, Gynecology, Opthalmology, General Surgery and Others), by Type (Absorbable Sutures and Non-Absorbable Sutures), Regional Outlook, Market Demand, Latest Trends, Absorbable and Non-Absorbable Sutures Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025. Analyzes current market size and upcoming 5 years growth of this industry.

A comprehensive analysis of the Absorbable and Non-Absorbable Sutures market is presented in this document, along with a brief overview of the segments in the industry. The study presents a feasible estimate of the current market scenario, including the Absorbable and Non-Absorbable Sutures market size with regards to the volume and renumeration. The report is a collection of significant data related to the competitive landscape of the industry. It also contains data with regards to several regions that have successfully established its position in the Absorbable and Non-Absorbable Suturesmarket.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/1271

Repot Scope:

Absorbable and Non-Absorbable Sutures Market Outlook by Applications:

Absorbable and Non-Absorbable Sutures Market Statistics by Types:

Absorbable and Non-Absorbable Sutures market competition by top Manufacturers:

A Glimpse over the highlights of the report:

Providing a thorough outline of the competitive and regional spheres of the Absorbable and Non-Absorbable Sutures market:

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/1271

Read this article:
Absorbable and Non-Absorbable Sutures Market Research, Recent Trends and Growth - News by aeresearch

The Ambulatory Healthcare IT market report contains thorough description, competitive scenario, wide product portfolio of key vendors and business strategy adopted by competitors along with their SWOT analysis and porters five force analysis. This report gives an actionable market insight to the clients with which they can create sustainable and profitable business strategies. This market research report is an absolute outline of the global industry which is penned down so that an unskilled individual as well as professional can easily extrapolate the entire Ambulatory Healthcare IT market within a few seconds. According to this market report, new highs will take place in the Ambulatory Healthcare IT market in 2019 2026.

Ambulatory Healthcare IT Market report has been crafted carefully to provide the latest insights into the significant aspects of the Market. This Ambulatory Healthcare IT Market research report is the exhaustive analysis of the market across the world. It offers an overview of the market including its definition, key drivers, key market players and key segments. In addition, the study presents statistical data on the status of the market and hence is a valuable source of guidance for companies and individuals interested in the Industry. Market segmentations break down the key sub sectors which make up the market.

Download Sample Report With All Graphs & Charts (Updated Values Are Listed In Sample Report): https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-ambulatory-healthcare-market

Ambulatory care is also referred as outpatient care. It is a medical care given on outpatient criteria such as consultation, rehabilitation, observation, intervention, diagnosis, and treatment services. Ambulatory care involves emergency care, primary care, ambulatory services, and others. In this intervention and surgery, overnight hospital stay is not required.

The report highly involves chapter wise explanation for every aspect of the market wherein the drivers, trends, opportunities, leading and trending segments are discussed in detail with specific examples. Profiles of leading players are also discussed along with their business expansion strategies.

Few of the major market competitors currently working in the global ambulatory healthcare IT market are AmSurg Corp, Surgical Care Affiliates, Surgery Partners, Healthway Medical Group, SurgCenter, Trillium Health Partners, Medical Facilities Corporation, Nueterra Capital, Aspen Healthcare, Suomen Terveystalo Oy, IntegraMed America, Inc., SHERIDAN HEALTHCARE, NueHealth, Athenahealth, GENERAL ELECTRIC, Optum, Inc., Apria Healthcare Group, Inc., DaVita Inc., LVL Medical, Fresenius Kabi AG, Sonic Healthcare among others.

Get TOC To Analyze Major Sections Of The Ambulatory Healthcare IT Market Report: https://www.databridgemarketresearch.com/toc/?dbmr=global-ambulatory-healthcare-market

The predictions featured in this report have been derived using proven research methods and standards. With this data, the research report serves as a source of information and analysis for every segment of the market, including but not restricted to: local markets, product, and application.

Global Ambulatory Healthcare IT Market By Type (Ambulatory Services, Primary Care Offices, Outpatient Departments, Emergency Departments, Surgical Specialty, Medical Specialty, Others), Modality (Hospital-affiliated, Freestanding), Surgery Type (Opthalmology, Orthopedics, Gastroenterology, Pain Management, Others), Application (Laceration Treatment, Bone Fracture Treatment, Emergency Care Service, Trauma Treatment)

Based on the geography

North America

South America

Asia and Pacific region

Middle east and Africa

Europe

Have look on the Premium Insights of the Report

The report covers 360-degree view of the market that encompasses statistical forecast, competitive landscape, all-inclusive segmentation and Strategic Suggestions

It provides in depth analysis by type, end user and regions.

Pricing analysis, Regulatory factor analysis and value chain analysis are mentioned in the report

In the end, this Ambulatory Healthcare IT Market report gives all the required to help to strive the business successfully.

Want Full Report? Enquire Here: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-ambulatory-healthcare-market

About Us

Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing Corporatesales@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475Mail:Corporatesales@databridgemarketresearch.comhttps://databridgemarketresearch.com

More here:
Ambulatory Healthcare IT Market Syndicated Research, Industrial Analysis With AmSurg Corp, Surgical Care Affiliates, Surgery Partners, Healthway...

As an aside to this article, reference is made to an ongoing global promo for the nomination of persons as Anti-Corruption Heroes of 2019, for the Sheikh Tamim Bin Hamad Al Thani International Anti-Corruption Excellence (ACE) Award.

The promo features the December 2018 presentation of the award to Mr. Nuhu Ribadu, the pioneer Executive Chairman of the Economic and Financial Crimes Commission (EFCC).

The high-point of the ceremony, held in Putrajaya, Malaysia, was not in the presentation with the plaque, but in the introduction of Ribadu as a man who refused a $15 million bribe.

That case involved a former Nigerian governor, who the EFCC, under Ribadu, was investigating over a monumental fraud in his eight-year rule of his state.

To possibly kill the investigation, the suspect offered Ribadu a $15 million bribe, but he turned it down, and deposited the hefty sum with the Central Bank of Nigeria (CBN), as a potential exhibit.

Sadly, the invitation for nomination for the 2019 ACE Award coincides with fresh attempts to ease Ibrahim Magu from the EFCC, where hes been Acting Chairman since November 2015.

Thus, the Ribadu anecdote serves to refresh our memory that, save the coming of Magu, the anti-corruption war thats at its nadir when he took over would have long been dead, and forgotten.

The EFCC, as the toughest job in the polity, is the single body that shines the light in the dark places where corruption and the corrupt cohabit to undermine the citizens patrimony.

Shining that light to expose their cohabitation is an arduous and risky task, demanding only the strong-willed to superintend. As the maxim goes, If you fight corruption, corruption will fight back.

And corruption in Nigeria is fighting back, with the non-confirmation of Magu aimed at stopping the crusade from uprooting corruption or reducing the scourge in the system.

The Senate of the Eighth National Assembly, conniving with outside forces located mainly in the government at national and sub-national levels, frustrated the confirmation of Magu.

The Senate, hiding behind unfavourable security reports by the Department of State Services (DSS), declined to confirm him twice, and yet pressured President Muhammadu Buhari to sack him.

Can the Director of the DSS, an aide, be more concerned about the screening than President Buhari, who nominated Magu twice despite the so-called unfavourable security reports?

If the rules were/are followed, Magu would be substantive Chairman of the EFCC, as the 1999 Constitution (as amended) does not envisage him to get approval of the Senate.

Section 171(1) of the Constitution provides that: Power to appoint persons to hold or act in the offices to which this section applies, and to remove persons so appointed from any such office, shall vest in the President.

Section 171(2)(a-e) states the offices to which this section applies, while subsection (d) designates the office as the Permanent Secretary in any Ministry or Head of any Extra-Ministerial Department of the Government of the Federation howsoever designated.

Does section 171(1)(2)(d) apply to Ibrahim Magu, who heads an Extra-Ministerial Department of the Government of the Federation in the EFCC?

Absolutely, argues Kabir G. Ibrahim, a legal practitioner and anti-corruption activist, who, in an article published by several websites in March 2017, dealt with the constitutional, statutory and judicial position of the law regarding the Magu saga.

He said: Flowing from the above constitutional provision, it is safe to posit that once the President appoints a person as Chairman of the EFCC, such person does not require the confirmation of the Senate

Citing the position of the law, as decided by Ayoola JSC (as he then was) in a case, I.N.E.C. v. Musa (2003) 3 NWLR (Pt. 806) 72 at 158 and 199, Mr. Ibrahim contends that in covering the field, the National Assembly cannot arrogate to itself powers that impeach the Constitution.

The Supreme Court ruling: Howsoever it is described, where the Constitution has covered the field as to the law governing any conduct, the provision of the Constitution is the authoritative statement of the law on the subject.

The supremacy of the National Assembly is subject to the overall supremacy of the Constitution. Accordingly, the National Assembly which the Constitution vests powers cannot go outside or beyond the Constitution

Why is Magu the sustained scorn of the lootelite (elite looters)? Because he remains the only pain in their butt. Their fear is his reiteration in January 2019 that the EFCC would secure more convictions than it did in 2018 when it got 312 convictions.

The records are not yet out, but another reason for wanting him out is what many Nigerians didnt know: Magu is one of the backbones of the acclaimed successes of the Ribadu era at the EFCC.

Hes described as a tougher cop than Ribadu. Hes patient, and interrogates suspects non-stop for hours, to wear them down. So, they would prefer to be quizzed by other interrogators.

Heres to show Magus toughness, as a lawyer told TheCable. Ribadu had asked him to release someone from detention and ask him to come back. But Magu, while saluting Ribadu, said, We shall release him, Sir, after he has answered our questions.'

Magu is about the longest top serving investigator in the EFCC, possessing a trove of dossiers on politically-exposed persons (PEPs), including, perhaps, the 23 completed case files of the 31 governors that Ribadu said were under investigation in 2006.

Hence, those who want him out are former and serving governors, lawmakers, ministers and heads of ministries, departments and agencies (MDAs); alleged cabals in the Presidency; and financial suckers in the private sector. So, as currently constituted, remove Magu from the EFCC, and these manipulators of the system for individual and group interests would have a field day stealing the nation blind.

Rather than answer to their charges, they parrot being witch-hunted. But Magu seems deaf to such nuances, focusing on the political determination, and exhortation of President Buhari that, If we do not kill corruption, corruption will kill us.

And Magus message: My dream is to leave a better Nigeria, free of corruption to the next generation. We cannot continue the way we are going; otherwise, there will be no Nigeria for the next generation.

Will his traducers allow him to achieve this self-imposed dream he vows to pursue with his last breath? Well, only President Buhari can determine that by renewing his mandate at the EFCC.

International convention forbids Magus removal midway into his tenure as Chairman of the Commonwealth Conference of Heads of Anti-Corruption Agencies in Africa. Doing so could also dent the image of Buhari as coordinator of Africas anti-corruption war.

Like Loading...

Related

Advertisements

Read the rest here:
Shades of corruption in Nigeria - New Telegraph Newspaper

Report byProf. Tissa Wijeratne MD FRACP FRCP (Edin) FRCP (London) FAHA FAAN (USA)

An exciting second day in Dubai started at 7.00 am with a masterclass in Neuro-Opthalmology. It was attended by a packed audience presented with an interestingassortment of cases by Dr Gordon Plant and Dr Vivek Laal.

The Plenary lecture on Reading in the Brain: Mapping the massive impact of literacy on brain circuits" was delivered by Prof. Stanislas Dehaene.

Dr Adrian Owen delivered the second plenary lecture on The Gray Zone and Brain Death."

Professor Russel Foster delivered the Soriano award lecture on light, circadian rhythms and sleep, mechanisms to new therapeutics. The first part of this brilliant lecture considered the discovery and clinical importance of the third photoreceptor system of the eye. The second part of the talk went on to discuss the connection between photoreceptor signal light, clockwork and sleep. He went on to discuss the detailed molecular changes during the circadian rhythm.

Dr Tedros, Director-General, World Health Organisation,delivered a video message on the WHO and recent collaborative outcomes.

Professor Raad Shakir, Immediate past president, WFN delivered the important news on ICD-11 and its impact on the future of neurology.

Professor William Carroll, President WFN delivered a lecture on the global role of World Federation of Neurology. Professor Bo Norrving delivered the much-awaited news on the implications of the reclassification of stroke as a neurological disease.

The WFN- Young neurologists, trainees and medical students informal gathering was a great success. Professor Tissa Wijeratne moderated the discussion. There was active participation. WFN trustees and the high-level leadership was available for the discussion and future of this group looks promising.

The number of parallel sessions covering dementia, headache disorders, movement disorders, MS and demyelinating disorders, dementia, neurooncology, advocacy, stroke medicine were highly successful.

The rest is here:
Highlights from Day Two of the World Congress of Neurology 2019 - WFN News

New York City, NY: October 29, 2019 Published via (WiredRelease) Global (United States, European Union and China) Active Pharmaceutical Ingredient Market Research Report 2019-2028. The MarketResearch.biz analyses the report based on customer demand, supply and demand status, competitive market scenario and industry policies. The Active Pharmaceutical Ingredient Market report covers all the minute details related to the industry like Technological Developments, Growth Opportunities, Threats to Market Growth, Innovative Strategies and Futuristic Market Trends.

Active Pharmaceutical Ingredient market report provides a comprehensive overview of current trends and new product development in the global Active Pharmaceutical Ingredient market. Featuring global and regional data and over top key players profiles, this report provides the ultimate guide to exploring opportunities in the keyword industry internationally. Some of the key players in the market are, Aurobindo Pharma, Sanofi, Cipla Limited, GlaxoSmithKline plc, Lupin Limited, Merck & Co., Mylan N.V., Teva Pharmaceutical Industries Ltd, Novartis Pharmaceuticals Corporation and Ipca Laboratories Ltd.

Download Free Sample Copy of Active Pharmaceutical Ingredient Market Report Study 2019-2028 At:https://marketresearch.biz/report/active-pharmaceutical-ingredient-market/request-sample

In this study, 2018 has been considered as the base year and 2019 to 2028 as the forecast period to estimate the market size for Active Pharmaceutical Ingredient. This report researches the worldwide Active Pharmaceutical Ingredient market size (capacity, value, production and consumption) in key regions like Europe, United States, Asia Pacific (Japan, China),Middle & Africaand other regions.

Active Pharmaceutical Ingredient Market Report Includes:

Industry Trends:Status and Outlook.

Product Revenue for Top Players: Growth Rate, Market Share, Current Market Situation Analysis.

Market Segment:manufacturing process, API type, drug type, therapeutic area, and region

Competitive Landscape: By Manufacturers, Development Trends.

Sales Revenue: Growth Rate, Market Share, Current Market Analysis.

Segments ofActive Pharmaceutical Ingredient Market:

Segmentation by Manufacturing Process: Captive Manufacturing, Contract Manufacturing. Segmentation by API Type: Synthetic API, Biological API. Segmentation by Drug Type: Prescription Drugs, Over-The-Counter Drugs. Segmentation by Therapeutic Area: Communicable Diseases, Oncology, Opthalmology, Cardiovascular Diseases, Diabetes, Respiratory Diseases, Other

Benefits of Purchasing Active Pharmaceutical Ingredient Market Report:

Analyst Support:Get your query resolved from our expert analysts before and after purchasing the report.

Customers Satisfaction: Our expert team will assist with all your research needs and customize the report.

Inimitable Expertise: Analysts will provide in-depth insights of the market.

Assured Quality: We focus on the quality and accuracy of the report.

Some key points of Global Active Pharmaceutical Ingredient Market research report:

Strategic Developments: The custom analysis gives the key strategic developments of the market, comprising R&D, new product launch, growth rate, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Market Features: The report comprises market features, capacity, capacity utilization rate, revenue, price, gross, production, production rate, consumption, import, export, supply, demand, cost, market share, CAGR, and gross margin. In addition, the report offers a comprehensive study of the market dynamics and their latest trends, along with market segments and sub-segments.

Analytical Tools: The Global Active Pharmaceutical Ingredient Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, feasibility study, and many other market research tools have been used to analyze the growth of the key players operating in the market.

Customize Report AndInquiry For The Active Pharmaceutical Ingredient Market Report:https://marketresearch.biz/report/active-pharmaceutical-ingredient-market/#inquiry

Research objectives of Active Pharmaceutical Ingredient Market:

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Conclusively, This report will provide you a clear view of each and every fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

ABOUT US:

MarketResearch.Biz is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge. The company offers services such as data mining, information management, and revenue enhancement solutions and suggestions. We cater to industries, individuals, and organizations across the globe, and deliver our offerings in the shortest possible turnaround time.

Contact Us At

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Tel: +1 347 826 1876

Website:https://marketresearch.biz

Email ID:[emailprotected]

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at[emailprotected].

More:
Global Active Pharmaceutical Ingredient Market Future 2019-2028 Including Threats, Futuristic Trends, Share, Size and Growth Opportunities - TheLoop21

Age-related macular degeneration with neovascularization of torn and rolled-up retinal pigmented ... [+] epithelium. (Photo By BSIP/UIG Via Getty Images)

Evidence continues to mount that a drug commonly prescribed for decades to treat a painful bladder condition known as interstitial cystitis (IC) is linked to retinal damage and toxicity. The retina is the light-sensing tissue at the back of the eye that allows us to see our world.

A 2018 study by Nieraj Jain, M.D, Assistant Professor of Ophthalmology, Emory University School of Medicine, Emory Eye Center, reported reading difficulty and visual changesespecially under dark conditionsamong six patients who had been taking the drug, Elmiron (pentosan polysulfate sodium, PPS) for an average of 15 years (range of 12-20 years).

Jain found that this group of six patients (median age 60; age range 37-62) all had atypical changes in their macula, the central part of the retina that allows us to have clear central vision. The patients described difficulty reading in dim light and diminished central visual acuity. The patients underwent genetic testing to determine if there was any basis for hereditary retinal loss, with none demonstrating any such evidence of a link. Other than Elmiron, there was no clear etiology based on other findings in their medical history that explained the concerning retinal changes found in all six patients. This led the researchers to issue a warning in 2018 that long-term use of Elmiron could potentially lead to retinal damage.

An additional 10 patientsage range of 38-68 years of agewith similar retinal changes were also reported by the same researchers in May of 2019, and presented at the 2019 annual meeting of the American Urological Association. The authors concluded that structural changes in the retina were certainly present, stating that it was unclear if stopping the medication would reverse the noted changes.

This ongoing concern led researchers from Kaiser Permanente in Northern California to study this phenomenon further in their own patients taking this medication.

They found that about 25% of their patients with significant exposure to Elmiron showed clear evidence of retinal damage. The concern is that toxicity from this medication could also appear to mimic other well-known retinal conditions, such as age-related macular degeneration (AMD) or an uncommon retinal condition known as pattern dystrophy.

The research was presented last week at AAO 2019, the 123nd Annual Meeting of the American Academy of Ophthalmology.

Interstitial cystitis (IC) is a cause of unrelenting pain in the bladder and pelvic regions of the lower abdomen. Its estimated that at least 1 million people, mostly women, in the U.S. have thispainful condition. While other pharmacologic (NSAIDS, antihistamines, bladder installation therapy) and behavioral approaches are available, Elmiron is the only FDA-approved medication to treat this painful and disabling condition. It effectively works by forming a protective coating on the inner lining of the bladder that reduces irritation by substances present in the urine. Since its a first-line drug used for many decades, its believed that at least several hundred of thousand people have likely been exposed to the drug.

Robin A. Vora, M.D., Consultant in Medical Retina, Chair of Ophthalmology, Kaiser Permanente, Northern California and colleagues (Amar Patel, M.D., and Ronald Melles, M.D.) described a woman on long-term Elmiron who was misdiagnosed as having a retinal dystrophy, a genetic cause of progressive vision loss that may lead to permanent blindness. As a result of their concern that more patients that could be affected, they decided to evaluate all 4.3 million Kaiser patients.

Searching the database, they identified 140 patients who had each taken an average of 5,000 pills over a period of 15 years. Ninety-one patients of the 140 were evaluated. The investigators captured retinal images and rated them as normal, possible abnormality, or definite abnormality. The toxicity involved specialized cells known as retinal pigmented epithelium (RPE) that help nourish precious vision-producing cells in the retina known as the macula. Twenty-two of the 91 patients showed clear signs of drug toxicity. The rate of toxicity increased with the amount of drug taken, from 11% of those taking 500 to 1,000 grams to 42% of those taking 1,500 grams or more.

Its unfortunate, said Vora. You have a patient with a chronic condition like interstitial cystitis, for which there is no cure and no effective treatment. They get put on these medications because its thought to have few side effects and few risks, and no one thinks about it again year after year, the number of pills theyre taking goes up and up.

Since there is no comprehensive data yet available to guide treatment, Vora recommends patients who are asymptomatic and show no retinal signs of toxicity be screened for retinal damage at least annually. Patients who are showing signs of toxicity need to have a conversation with their health care provider whether to stop taking the medication.

Urologists and gynecologists are the primary medical providers for patients with IC. Elizabeth Kavaler, M.D., a urologist with Lenox Hill Hospital in New York City, suggested active retinal surveillance of patients would be prudent in managing patients with IC.

The impact of IC on the life of people who suffer with it cannot be minimized, she said. For women who have had good success with Elmiron, and are able to live their lives without chronic, unremitting pain, perhaps yearly or biyearly retinal exams should be done.

The mechanism behind the toxicity is unclear, but may involve the production of a toxic metabolite of Elmiron. Jains team has suggested that a component of Elmiron, a glycosaminoglycan (GAG) with a highly negative charge, may also play a potential role in disrupting the interphotoreceptor matrix in the macula. Other research by Singh and colleagues from Cleveland Clinic has suggested that Elmiron acts as an antagonist of signaling pathways related to fibroblast growth factor (FGF), a protein integral to retinal maintenance and function. There is no research that has yet elucidated the exact mechanism.

Jain has been in contact with the FDA, which is aware of his and other research linking Elmiron to retinal damage. To date, the FDA has not taken any action or issued any alerts regarding the toxicity of the medication.

The researchers are expressing growing concern that the presentation of these patients is unique and does not resemble any other identified acquired or hereditary maculopathy. At this time, an association or link with PPS exposure and maculopathy exists, but no definitive cause and effect relationship. The broader question is whether visual problems may be an unrecognized effect of IC; there have been no studies to link these two conditions as of yet.

If the changes are picked up early, its unclear whether retinal damage is reversible by discontinuing the medication. Long term monitoring will be required to make this clinical determination. For those with no clear evidence of damage who are currently taking the medication, close monitoring is critical, according to Vora and Jain. However, in later stages, toxicity can resemble late-stage dry atrophic age-related macular degeneration (AMD) and result in permanent vision loss.

Here is the original post:
New Study Adds Concern That Medication To Treat Painful Bladder Condition Linked To Vision-Threatening Eye Condition - Forbes

2019 Celibate Clergy Candidatesfor Election to the Episcopacyof the Greek Orthodox Archdiocese of America

Updated on Oct.17, 2019

Download as PDF

Current Assignment: Transfiguration Of Christ Church, Mattituck, NYDirect Archdiocesan District

Date of birth: May 15, 1968Education: B.A., Hellenic College, Brookline, MA (1990)M.Div., Holy Cross, Brookline, MA (1993)

Ordinations/OffikionTo Diaconate: April 19, 1995To Priesthood: June 18, 1995Archimandrite: August 5, 2018

Current Assignment: Holy Cross Church, Whitestone, NYDirect Archdiocesan District

Date of birth: August 18, 1969Education: B.S., Computer Technology, Northeastern University, Boston, MA (1994)M.Div., Holy Cross, Brookline, MA (2004)

Ordinations/OffikionTo Diaconate: August 17, 2003To Priesthood: August 24, 2003Archimandrite: April 15, 2006

Current Assignment: Chancellor, Metropolis of Chicago

Date of birth: October 4, 1952Education: B.A., Hellenic College, Brookline, MA (1975)M.Div., Holy Cross, Brookline, MA (1978)

Ordinations/OffikionTo Diaconate: Sep. 14, 1980To Priesthood: October 5, 1980Archimandrite: May 12, 1985

Current Assignment:Saint John the Baptist Church, New York, NYDirect Archdiocesan District

Date of birth: November 15, 1945Education: A.A., Philosophy/Psychology, Kingsborough Community College, Brooklyn, NY (1992)B.A., Byzantine & Modern Greek Studies, Queens College, Queens, NY (1998)M.Div., Holy Cross, Brookline, MA (2005)

Ordinations/OffikionTo Diaconate: March 27, 2005To Priesthood: September 18, 2005Archimandrite: January 7, 2012

Current Assignment:Saint George Cathedral, Philadelphia, PAMetropolis of New Jersey

Date of birth: September 4, 1964Education: Lic., Theology, Aristoteleion University, Thessaloniki, GR (1991)M.A. Theology, Belford University School of Theology, Humble, TX (2008)M.A. Theology, Aristoteleion University, Thessaloniki, GR (2014)M.A. Ecclesiastical History, Seton Hall University-Immaculate Conception Theological Seminary (2015)PhD. Aristoteleion University, Thessaloniki, GR (2018)

Ordinations/OffikionTo Diaconate: November 24, 1985To Priesthood: January 12, 1992Archimandrite: January 12, 1992

Current Assignment:Saint George Church, Downey, CAMetropolis of San Francisco

Date of birth: August 13, 1957Education:strong> B. S., Biology, University of Richmond, VA (1979)M.S., Biology, University of Richmond, VA (1981)M.Div., Holy Cross, Brookline, MA (1987)

Ordinations/OffikionTo Diaconate: December 14, 1991To Priesthood: December 15, 1991Archimandrite: July 23, 1995

Current Assignment:Hellenic College/Holy Cross, Brookline, MADirect Archdiocesan District

Date of birth: June 7, 1954Education: M.Div., Holy Cross, Brookline, MA (1979)M.A., Byzantine History, Penn State, PA (1986)Ph.D., Byzantine History, Penn State, PA (1992)

Ordinations/OffikionTo Diaconate: December 9, 1979To Priesthood: December 23, 1979Archimandrite: May 16, 1998

Current Assignment: Saint George Church, Piscataway, NJMetropolis of New Jersey

Date of birth: December 4, 1964Education: B.A., Modern Languages, Citadel University, Charleston, SC (1987)M.Div., Holy Cross, Brookline, MA (1990)

Ordinations/OffikionTo Diaconate: February 2, 1991To Priesthood: May 11, 1996Archimandrite: May 11, 1996

Current Assignment: Kimisis Tis Theotokou Church, Brooklyn, NYDirect Archdiocesan District

Date of birth: September 11, 1944Education: B.A., Hellenic College, Brookline, MA (1973)M.Div. and S.T.M., Holy Cross, Brookline, MA (1974)

Ordinations/OffikionTo Diaconate: May 6, 1973To Priesthood: November 4, 1974Archimandrite: May 21, 1980

Current Assignment: Saints Constantine & Helen Church, Palos Hills, ILMetropolis of Chicago

Date of birth: April 14, 1967Education: B.A., Hellenic College, Brookline, MA (1985)M.Div., Holy Cross School of Theology, Brookline, MA (1992)

Ordinations/OffikionTo Diaconate: December 19, 2010To Priesthood: March 20, 2011Archimandrite: January 6, 2017

Current Assignment: Saint Barbara Church, Durham, NCMetropolis of Atlanta

Date of birth: March 9, 1957Education: B.A., Hellenic College, Brookline, MA (1980)M.Div., Holy Cross, Brookline, MA (1983)

Ordinations/OffikionTo Diaconate: September 14, 1986To Priesthood: October 19, 1986Archimandrite: June 6, 1999

Current Assignment: Saint Nicholas Church, Oak Lawn, ILMetropolis of Chicago

Date of birth: January 22, 1976Education: B.A., Hellenic College, Brookline, MA (2003)M.Div., Holy Cross, Brookline, MA (2006)

Ordinations/OffikionTo Diaconate: July 2, 2006To Priesthood: December 3, 2006Archimandrite: December 6, 2016

Current Assignment: Annunciation Cathedral, Baltimore, MDMetropolis of New Jersey

Date of birth: July 30, 1965Education: B.A., Hellenic College, Brookline, MA (1992)M.Div., Holy Cross, Brookline, MA (1994)

Ordinations/OffikionTo Diaconate: February 11, 1996To Priesthood: June 9, 1996Archimandrite: August 4, 2002

Current Assignment: Holy Apostles/Saints Peter & Paul Church, Haverhill, MAMetropolis of Boston

Date of birth: August 5, 1965Education: B.A., Hellenic College, Brookline, MA (1987)M.Div., Holy Cross, Brookline, MA (1990)ThD., Aristotelion University (2017)

Ordinations/OffikionTo Diaconate: January 30, 1991To Priesthood: February 17, 1991Archimandrite: December 31, 1996

Current Assignment: Holy Trinity Cathedral, Salt Lake City, UTMetropolis of Denver

Date of Birth: August 25, 1969Education: B.A., Hellenic College, Brookline, MA (1996)M.Div., Holy Cross, Brookline, MA (1999)

Ordinations/OffikionTo Diaconate: September 14, 1999To Priesthood: December 5, 1999Archimandrite: March 24, 2004

Current Assignment: Transfiguration of Christ Church, Corona, NYDirect Archdiocesan District

Date of Birth: October 11, 1964Education: B.A., Political Science, New York Institute of Technology, New York, NYCertificate, Antiochian House of Studies (2010)M.Div., Holy Cross, Brookline, MA (2015)

Ordinations/OffikionTo Diaconate: November 13, 2010To Priesthood: August 6, 2015Archimandrite: November 30, 2015

Current Assignment: Unassigned

Date of birth: January 1, 1958Education: M.A., Church Services, Hellenic College, Brookline, MA (1986)M.Div, Holy Cross, Brookline, MA (2007)After Hellenic College (1986) he traveled to the Monastery of Archangel Michael, Rhodos, where he was tonsured a monastic on October 21, 1991.

Ordinations/OffikionTo Diaconate & Priesthood: October 11, 1992 (Monastery of Archangel Michael, Rhodos)Archimandrite: October 20, 1994 (Church of St. Gerasimos, Pylona, Rhodos)NOTE: In 2015 incardinated into the Greek Orthodox Archdiocese of America from the Greek Orthodox Archdiocese of New Zealand. (Note: The number of years of service listed in the GOA Charter is no less than 5 years in the GOA.)

Current Assignment: Saint Demetrios Cathedral, Astoria, NYDirect Archdiocesan District

Date of birth: June 6, 1967Education: B.S., Electrical Engineering, Polytechnic University, NYC (1990)M.S., Electrical Engineering, Polytechnic University, NYC (1995)M.Div., St. Vladimirs Seminary, Crestwood, NY (2000)

Ordinations/OffikionTo Diaconate: June 16, 2002To Priesthood: January 18, 2004Archimandrite: January 18, 2004

Current Assignment: Three Hierarchs Church, Brooklyn, NYDirect Archdiocesan District

Date of birth: July 23, 1940Education: B.A., St. Johns University, Queens, NY (1962)M.Div., Holy Cross, Brookline, MA (1966)Lic., Theology, Aristotelion University, Thessaloniki, GR (1974)Diploma, Theology, Ecumenical Institute at Bossey, University de Geneve (1975)

Ordinations/OffikionTo Diaconate: January 30, 1966To Priesthood: May 29, 1966Archimandrite: May 29, 1971

Current Assignment: Lay Profession (Opthalmologist)Metropolis of New Jersey

Date of birth: April 22, 1977Education: B.A., Biology, Cornell University, Ithaca, NY (1998)MS, Science, SUNY, New York, NY (2003)O.D., Opthalmology, SUNY, New York, NY (2003)M.Th., St. Vladimirs Orthodox Seminary, Yonkers, NY (2010)

Ordinations/OffikionTo Diaconate: December 27, 2010To Priesthood: March 6, 2016Archimandrite: December 24, 2016

Current Assignment: Saints Constantine & Helen Church, Boise, IDMetropolis of Denver

Date of birth: November 7, 1945Education: Diploma*, Theology, St. Tikhons Seminary, South Canaan, PA (1973)B.A., Sociology, Kings College, Wilkes-Barre, PA (1974)* St Tikhons was granted the right to confer the M.Div. in 1988

Ordinations/OffikionTo Diaconate: December 21, 1975To Priesthood: October 3, 1976Archimandrite: November 4, 2001

Current Assignment: Saint George Cathedral, Manchester, NHMetropolis of Boston

Date of birth: April 21, 1957Education: B.S., Business Administration, Western New England College, Springfield, MA (1979)M.Div., Holy Cross, Brookline, MA (2005)

Ordinations/OffikionTo Diaconate: August 22, 2004To Priesthood: May 15, 2005Archimandrite: January 10, 2010

Current Assignment: Saint Anna Church, Roseville, CAMetropolis of San Francisco

Date of birth: September 20, 1971Education: B.A., Hellenic College, Brookline, MA (1993)M.Div., Holy Cross, Brookline, MA (1996)M.S., Science, Northeastern University, Boston, MA (1996)

Ordinations/OffikionTo Diaconate: November 17, 1996To Priesthood: February 2, 1997Economos: July 25, 2013

( )

. . (). . (). . (). . (). . (). . (). . (). . ()

. . (). . (). . (). . ()

, . . (). . (). . (). . (). . (). . (Katre)

Read the original post:
2019 Celibate Clergy Candidates for Election to the Episcopacy - Official Documents - Greek Orthodox Archdiocese of America

Ambulatory Healthcare IT Market report uses a range of steps for collecting, recording, analysing and interpreting market data to make this report all-inclusive. market report also endows with the list of the leading competitors and their moves such as joint ventures, acquisitions, and mergers etc.

Ambulatory Healthcare IT Market research report study presents data corralled through primary and secondary research methodologies exploring the global market. The detailed data provided in the report and the industry standard models use to analyze it make this industry report highly beneficial for the clients. This Ambulatory Healthcare IT Market research report describes the market in detail in terms of economics and regulatory factors that are currently shaping the markets growth trajectory, the regional segmentation of the global market and an analysis of the markets downstream and upstream value and supply chains are also included in the report.

Get Sample Report With All Graphs & Charts: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-ambulatory-healthcare-market

Ambulatory care is also referred as outpatient care. It is a medical care given on outpatient criteria such as consultation, rehabilitation, observation, intervention, diagnosis, and treatment services. Ambulatory care involves emergency care, primary care, ambulatory services, and others. In this intervention and surgery, overnight hospital stay is not required.

The Ambulatory Healthcare IT Market research report provides the comprehensive and in depth study of the market which sheds light on each segment and provides precise investigation considering attractiveness, demand production and sales volume and growth prospects. Moreover this Ambulatory Healthcare IT Market report features the segmentation analysis to facilitate clients with a shrewdness that helps them to select appropriate segments of the Ambulatory Healthcare IT Market

Global Ambulatory Healthcare IT Market By Type (Ambulatory Services, Primary Care Offices, Outpatient Departments, Emergency Departments, Surgical Specialty, Medical Specialty, Others), Modality (Hospital-affiliated, Freestanding), Surgery Type (Opthalmology, Orthopedics, Gastroenterology, Pain Management, Others), Application (Laceration Treatment, Bone Fracture Treatment, Emergency Care Service, Trauma Treatment), Geography (North America, South America, Europe, Asia-Pacific, Middle East & Africa) Industry Trends and Forecast to 2026

Avail The TOC Here, To Get Premium Insights About The Ambulatory Healthcare IT Market Report: https://www.databridgemarketresearch.com/toc/?dbmr=global-ambulatory-healthcare-market

Few of the major market competitors currently working in the global ambulatory healthcare IT market are AmSurg Corp, Surgical Care Affiliates, Surgery Partners, Healthway Medical Group, SurgCenter, Trillium Health Partners, Medical Facilities Corporation, Nueterra Capital, Aspen Healthcare, Suomen Terveystalo Oy, IntegraMed America, Inc., SHERIDAN HEALTHCARE, NueHealth, Athenahealth, GENERAL ELECTRIC, Optum, Inc., Apria Healthcare Group, Inc., DaVita Inc., LVL Medical, Fresenius Kabi AG, Sonic Healthcare among others.

Summary of the research report

Want Full Report? Make Enquiries: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-ambulatory-healthcare-market

About Us

Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing Corporatesales@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475Mail:Corporatesales@databridgemarketresearch.comhttps://databridgemarketresearch.com

Read more from the original source:
Ambulatory Healthcare IT Market Trends, Syndicated Reports With AmSurg Corp, Surgical Care Affiliates, Surgery Partners, Healthway Medical Group,...

Opthalmology Drugs and Devices Market Report is a complete assessment of current status, trends and respective shares of some of the most prominent players in this landscape. The study contains thoughtful insights, facts, Opthalmology Drugs and Devices historical data, and statistically supported and industry-validated market data. This Opthalmology Drugs and Devices report also explores Business models, Key strategies and Growth opportunities in upcoming years.

The Opthalmology Drugs and Devices market report examines the economic status and prognosis of worldwide and major regions, in the prospect of all players, types and end-user application/industries; this report examines the most notable players in major and global regions, also divides the Opthalmology Drugs and Devices market by segments and applications/end businesses.

Request for Free Sample Copy at: http://www.researchreportcenter.com/request-sample/1254902

Merck (US), Pfizer (US), Roche Holdings (Switzerland), Santen Pharmaceutical(Japan), Abbott Medical Optics (US), Alcon (Switzerland), Bausch & Lomb (US), Carl Zeiss Meditec (Germany), Essilor International S.A. (France), Johnson & Johnson (US), Nidek(Japan), Topcon Corporation (Japan)

Global Opthalmology Drugs and Devices Market insights cover traits, growth, and size, segmentation, regional retreats, competitive landscape, shares, trends, and plans. The attributes part of this Opthalmology Drugs and Devices report defines and explains the growth. The market size department gives industry earnings, covering the historical growth of this and predicting the long run. Opthalmology Drugs and Devices Drivers and restraints with the variables affecting the growth of this market. The segmentations divide the essential Opthalmology Drugs and Devices sub-industries that form the market.

North America, China, Rest of Asia-Pacific, UK, Europe, Central & South America, Middle East & Africa

Get Discount on this Report: http://www.researchreportcenter.com/check-discount/1254902

The Opthalmology Drugs and Devices analysis incorporates historical data from 2014 to 2019 and predictions until 2025 helping to make the reports a valuable resource for industry executives, promotion, product and sales managers, advisers, analysts, and different people trying to find vital Opthalmology Drugs and Devices industry data in readily accessible records with clearly exhibited tables and charts.

Customization of the Report: This report can be customized as per your needs for additional data or countries.Please connect with our sales team (sales@researchreportcenter.com)

The rest is here:
Opthalmology Drugs and Devices Market Professional Survey and In-Depth Analysis Research Report Foresight to 2025 - Finance Daily Tribune

Active Pharmaceutical Ingredients (API) market size was valued at USD 158.5 billion in 2016 and is projected to reach to USD 297.4 billion by 2026 at a CAGR of 6.5%.This is a comprehensive global report focused on the current and future prospects of the active pharmaceutical ingredients market. This report is a consolidation of primary and secondary research, which provides market size, share, dynamics, and forecast for various segments and sub-segments considering the macro and microenvironmental factors. An in-depth analysis of past trends, future trends, demographics, and technological advancements for the active pharmaceutical ingredients market has been done in order to calculate the growth rates for each segment and sub-segments.

An active pharmaceutical ingredient is a biologically active portion of a pharmaceutical drug intended to perform certain pharmacological actions or have prominent effects for the diagnosis, cure, treatment or prevention of chronic and acute diseases.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/1816

The rising prevalence of chronic diseases and increasing uptake of biopharmaceuticals is expected to majorly drive the market growth.

As per data published by the World Health Organization (WHO), chronic disease prevalence is anticipated to rise by 57.0% by the year 2020. The number of people suffering from diabetes in developing countries was 84.0 million in 1995, which is projected to increase by 2.5-fold to 228.0 million in 2025. Chronic diseases include diabetes, obesity, and cardiovascular diseases, cancer, neurological diseases, and other diseases; the rise in prevalence of these diseases are augmenting the demand for treatment that may support the market growth over the forecast period.

Furthermore, augmented demand for rapid-acting & efficient drugs and the emergence of innovative drug manufacturing facilities are expected to assist in market growth during the forecast period.

Loss of drug exclusivity is impeding the revenue growth!

Patent expiration is accountable for the huge loss for pharmaceutical firms in terms of revenue, which is anticipated to impede the market growth during the forecast period.

The biotech APIs segment is expected to witness significant market growth.

The biotech APIs segment is expected to register comparatively higher CAGR over thee forecast period owing to high R&D for novel biosimilar drugs, escalating demand for protein-based therapeutics, and rising key traditional manufacturers focus toward biological drugs.

The branded/innovative drugs segment spearheaded the market.

A surge in prescription rates and drug prices coupled with higher spending on R&D activities are expected to contribute to the dominance of the branded/innovative drugs segment.

The merchant manufacturers segment is expected to witness lucrative market growth.

Worldwide rising outsourcing of API/drug molecule formulation from drug manufacturers in order to eliminate the need for heavy investment in manufacturing processes.

North America is expected to hold a major chunk of the market during the forecast period.

North America is anticipated to hold substantial market share over next ten years owing to the presence of favorable government initiatives, changing lifestyle leads to the development of diseases, rising investment on R&D, and technological developments in drug manufacturing processes.

Key Highlights:

Active pharmaceutical ingredients market size analysis and forecast Comprehensive study and analysis of market drivers, restraints, and opportunities influencing the growth of the active pharmaceutical ingredients market Active pharmaceutical ingredients market segmentation on the basis of synthesis type, drug type, manufacturer type, therapeutic area, and geography (regional) Active pharmaceutical ingredients market strategic analysis with respect to individual growth trends, future prospects along with a contribution of various sub-market stakeholders have been considered under the scope of a study Active pharmaceutical ingredients market analysis and forecast for five major regions such as North America, Europe, Asia Pacific, Latin America, and MEA. Profiling of key industry players, their strategic perspective, market positioning and analysis of core competencies Competitive landscape of the key players operating in the active pharmaceutical ingredients market including competitive developments, investments, and strategic expansion

Years that have been considered for the study are as follows:

Base Year 2016 Estimated Year 2017 Forecast Period 2017 to 2026

For company profiles, 2016 has been considered as the base year. In cases, wherein information was unavailable for the base year, the years prior to it have been considered.

Research Methodology:

The market is estimated by triangulation of data points obtained from various sources and feeding them into a simulation model created individually for each market. The data points are obtained from paid and unpaid sources along with paid primary interviews with key opinion leaders (KOLs) in the market. KOLs from both, demand and supply side were considered while conducting interviews to get an unbiased idea of the market. This exercise was done at a country level to get a fair idea of the market in countries considered for this study. Later this country-specific data was accumulated to come up with regional numbers and then arrive at the market value for active pharmaceutical ingredients market.

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/1816

Some of the key players of the active pharmaceutical ingredients market include:

AbbVie Inc. Bristol-Myers Squibb Company Boehringer Ingelheim GmbH Cipla Inc. Merck & Co., Inc. Eli Lilly and Company Mylan N.V. Teva Active Pharmaceuticals Industries Ltd. Aurobindo Pharma Sun Pharmaceutical Industries, Ltd. Dr. Reddys Laboratories Ltd. Albemarle Corporation

Key Target Audience:

Healthcare companies Corporate healthcare entities Government agencies Market research and consulting firms Venture capitalists Technical StudentsScope of the Active Pharmaceutical Ingredients Market Report:

The research report segments the active pharmaceutical ingredients market based on synthesis type, drug type, manufacturer type, therapeutic area, and geography.Active Pharmaceutical Ingredients Market, By Synthesis Type

Biotech Monoclonal Antibodies Recombinant Proteins Vaccines SyntheticActive Pharmaceutical Ingredients Market, By Drug Type

Branded Drugs Generic Drugs Over-the-counter (OTC) DrugsActive Pharmaceutical Ingredients Market, By Manufacturer Type

Captive Manufacturers Merchant ManufacturersActive Pharmaceutical Ingredients Market, By Therapeutic Area

Cardiology Pulmonology Opthalmology Neurology Oncology Orthopedics OthersActive Pharmaceutical Ingredients Market, By Geography

North America U.S. Canada Europe UK Germany France Italy Spain Rest of Europe Asia Pacific Japan China India Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America MEA South Africa Saudi Arabia Rest of MEA

Geographic Analysis:

Breakdown of North America Active Pharmaceutical Ingredients Market Breakdown of Europe Active Pharmaceutical Ingredients Market Breakdown of Asia Pacific Active Pharmaceutical Ingredients Market Breakdown of Latin America Active Pharmaceutical Ingredients Market Breakdown of MEA Active Pharmaceutical Ingredients Market

MAJOR TOC OF THE REPORT

Chapter One: Active Pharmaceutical Ingredients (API) Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Active Pharmaceutical Ingredients (API) Market Competition, by Players

Chapter Four: Global Active Pharmaceutical Ingredients (API) Market Size by Regions

Chapter Five: North America Active Pharmaceutical Ingredients (API) Revenue by Countries

Chapter Six: Europe Active Pharmaceutical Ingredients (API) Revenue by Countries

Chapter Seven: Asia-Pacific Active Pharmaceutical Ingredients (API) Revenue by Countries

Chapter Eight: South America Active Pharmaceutical Ingredients (API) Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Active Pharmaceutical Ingredients (API) by Countries

Chapter Ten: Global Active Pharmaceutical Ingredients (API) Market Segment by Type

Chapter Eleven: Global Active Pharmaceutical Ingredients (API) Market Segment by Application

Chapter Twelve: Global Active Pharmaceutical Ingredients (API) Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Active Pharmaceutical Ingredients (API) Market Report at: https://www.maximizemarketresearch.com/market-report/active-pharmaceutical-ingredients-api-market/1816/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

The rest is here:
Active Pharmaceutical Ingredients (API) Market Global Industry Analysis and Forecast (2017-2026 - Markets Gazette

It's almost time for the American Academy of Opthalmology's (AAO) annual meeting again, and this year's event will contain some high-stakes presentations. This year, all three of these biopharmaceutical companies will present clinical trial results that could send their stock prices soaring -- or tumbling.

Data source: Company Filings, Yahoo! Finance.

Which stocks have the best chance to climb this week? Here's what to look out for when investigators from each company present their results at AAO.

Image source: Getty Images.

Ophthalmologists have been treating age-related macular degeneration (AMD) and similar causes of blindness with vascular endothelial growth factor (VEGF) inhibitors like Eylea fromRegeneronfor a long time. Sadly, many patients continue losing their sight despite VEGF treatment and Kodiak has an elegant solution to the problem.

Ophthalmologists would like to apply a VEGF treatment to the retina every few days but nobody wants to visit the doctor to get a needle in the eye more often than necessary. Four- and eight-week intervals are the norm and toward the end of each interval, there are days where treatments have already been depleted. That allows new blood vessels to begin invading the retina until the next generation.

On Friday, Oct. 11, 2019, Kodiak will present durability data from an ongoing study with patients that are losing their vision to AMD or a related disorder. The company's lead candidate, KSI-301 is a VEGF antibody with long, heavy hair extensions calledphosphorylcholine. That's the same biopolymer used in drug-eluting stents.

Kodiak's KSI-301 appeared to work well after at a 12-week checkup, but that's not very long. If durability data presented on Friday continues to impress, this stock's terrific run-up in 2019 could go much further.

Image source: Getty Images.

In September, Adverum Biotechnologies stock sank after the company reported 24-week data for the first six patients treated with a single injection of ADVM-022, its experimental gene therapy for many of the same AMD patients that Kodiak's aiming at. A one-time treatment that keeps invading blood vessels at bay for the rest of a patient's life would be a welcome improvement, but patients experienced an average loss of two letters when their best-corrected visual acuity (BCVA) scores were assessed.

While Adverum hailed the results as a success because none of the patients received rescue injections with a regular VEGF treatment, some observers wondered why rescue injections weren't provided. According to Adverum, AMD wasn't responsible for the observed vision losses, and the gene therapy actually worked as expected.

On Friday, Oct. 11, Adverum will present more details from the disappointing 24-week data that hammered the stock a month earlier. If the company can convince investors that the results they saw earlier contained strong signs of encouragement, the stock could regain some of last month's losses.

Unfortunately, ADVM-022 doesn't appear to work any better than AVA-101, another experimental gene therapy that Adverum quit developing years ago when the company was still named Avalanche Biotechnologies. Investors should know that the company ended up settling a class action lawsuit for $13 million rather than try to defend itself against allegations of false statements and omissions of important information that would have sent investors running for the hills much earlier than they did in 2015.

Image source: Getty Images.

At last year's AAO conference, Regenexbio stock soared after the company presented early clinical trial results for RGX-314, an experimental gene therapy for AMD patients. In May, the company completed dosing all 42 patients in the trial with five escalating dosages of RGX-314. On Friday, Oct. 11, Regenexbio will present 18-month data for cohort three and interim data from cohorts four and five.

Only three out of six patients in group three were still VEGF injection-free 18 months after a single dose of RX-314, so success with a larger dosage is a must for this program.If interim data from cohorts four and five lead to a stronger response that keeps invasive blood vessel formation from robbing patients of their vision.

So far, we've seen dosage-dependent responses in cohorts one through three, and a continuation of this trend in cohorts four and five could send this biotech stock through the roof.

Image source: Getty Images.

While Adverum's gene therapy seems headed for further trouble, Regenexbio's gene therapy has a pretty good shot at impressing investors later this week. Further down the line, however, Kodiak Sciences probably has the best chance to successfully launch a new drug for the treatment of AMD and related causes of blindness.

There's a lot to like about single-shot solutions from Adverum and Regenexbio, but they could end up solving a problem that isn't really a big problem anymore. That's because Kodiak's candidate might be able to outperform standard care with just a couple of injections per year instead of every four to 12 weeks as is the norm today.

View original post here:
3 Blindness-Fighting Biotech Stocks That Could Surge This Week - The Motley Fool

The Ambulatory Healthcare IT Market report has been crafted carefully to provide the latest insights into the significant aspects of the Market. This Ambulatory Healthcare IT Market research report is the exhaustive analysis of the market across the world. It offers an overview of the market including its definition, key drivers, key market players and key segments. In addition, the study presents statistical data on the status of the market and hence is a valuable source of guidance for companies and individuals interested in the Industry. Market segmentations break down the key sub sectors which make up the market.

Download Sample Report With All Graphs & Charts (Updated Values Are Listed In Sample Report): https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-ambulatory-healthcare-market

Ambulatory care is also referred as outpatient care. It is a medical care given on outpatient criteria such as consultation, rehabilitation, observation, intervention, diagnosis, and treatment services. Ambulatory care involves emergency care, primary care, ambulatory services, and others. In this intervention and surgery, overnight hospital stay is not required.

The report highly involves chapter wise explanation for every aspect of the market wherein the drivers, trends, opportunities, leading and trending segments are discussed in detail with specific examples. Profiles of leading players are also discussed along with their business expansion strategies.

Few of the major market competitors currently working in the global ambulatory healthcare IT market are AmSurg Corp, Surgical Care Affiliates, Surgery Partners, Healthway Medical Group, SurgCenter, Trillium Health Partners, Medical Facilities Corporation, Nueterra Capital, Aspen Healthcare, Suomen Terveystalo Oy, IntegraMed America, Inc., SHERIDAN HEALTHCARE, NueHealth, Athenahealth, GENERAL ELECTRIC, Optum, Inc., Apria Healthcare Group, Inc., DaVita Inc., LVL Medical, Fresenius Kabi AG, Sonic Healthcare among others.

Get TOC To Analyze Major Sections Of The Ambulatory Healthcare IT Market Report: https://www.databridgemarketresearch.com/toc/?dbmr=global-ambulatory-healthcare-market

The predictions featured in this report have been derived using proven research methods and standards. With this data, the research report serves as a source of information and analysis for every segment of the market, including but not restricted to: local markets, product, and application.

Global Ambulatory Healthcare IT Market By Type (Ambulatory Services, Primary Care Offices, Outpatient Departments, Emergency Departments, Surgical Specialty, Medical Specialty, Others), Modality (Hospital-affiliated, Freestanding), Surgery Type (Opthalmology, Orthopedics, Gastroenterology, Pain Management, Others), Application (Laceration Treatment, Bone Fracture Treatment, Emergency Care Service, Trauma Treatment)

Want Full Report? Enquire Here: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-ambulatory-healthcare-market

About Us

Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing Corporatesales@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475Mail:Corporatesales@databridgemarketresearch.comhttps://databridgemarketresearch.com

Read the rest here:
Ambulatory Healthcare IT Market Insights, Online Research With AmSurg Corp, Surgical Care Affiliates, Surgery Partners, Healthway Medical, SurgCenter,...

The renowned surgical director of our practice, Christopher T. Coad, MD, FACS has gathered a team of highly gifted staff to create a boutique practice in New York City that brings a comprehensive approach to patients vision, LASIK and cosmetic needs. Our state-of-the-artfacility boasts an art gallery in the reception area, a comfortable relaxed environment suggestive of a spa and an in-office surgical suite. Our doctors train other physicians and are often featured in the press.

Dr. Coad specializes in the most advanced vision correction procedures including LASIK, PRK, Visian ICL, premium intraocular lens implants, and no-stitch cataract surgery. He has been performing laser vision correction since its approval by the FDA in the early 1990s. Dr. Coad has been named a Top Doctor in Ophthalmology by Castle Connolly Medical.

Competitive prices, extended office hours, participation in most health care plans, and interest-free financing have helped us gain the trust of over 60,000 patients.

Giving Back to the CommunityWeve been serving our community for two decades and donate to organizations such as amfAR, Callen Lorde, ESPA, glaad, HRC, and The Little Baby Face Foundation. We have special programs to treat patients in financial need who suffer from HIV related lipodystrophy and are setting up a foundation to help treat victims of bullying and spousal abuse in the LGBT community. Our waiting room also serves as an art gallery to exhibit the work of local artists and fund charities. To find out more about the ways we support art and our community, visit us on Facebook.

Chelsea Eye Ophthalmology is downtown Manhattans leading eye care andlaser visioncenter. Founded in 1989, the facility expanded 10 years later to its present location in the heart of Chelsea's gallery district in NYC.

Dr. Coad specializes in the most advanced vision correction procedures includingLASIK,PRK,Visian ICL,premium intraocular lens implants, andno-stitch cataract surgery. He has been performing laser vision correction since its approval by the FDA in the early 1990s.

Dr. Jason Cheung, works closely with Dr. Coadto provide comprehensive eye care includingcontact lens servicesand treatments formedical eye conditions.

Competitive prices, extended office hours, participation in mosthealth care plans, andinterest-free financinghave helped us gain the trust of over 60,000 patients.

Giving Back to the CommunityWeve been serving our community for two decades and donate to organizations such as amfAR, Callen Lorde, ESPA, glaad, HRC, and The Little Baby Face Foundation. We have special programs to treat patients in financial need who suffer from HIV related lipodystrophy and are setting up a foundation to help treat victims of bullying and spousal abuse in the LGBT community. Our waiting room also serves as anart galleryto exhibit the work of local artists and fund charities. To find out more about the ways we support art and our community,visit us on Facebook.

"Im so happy I chose Dr. Coad as my physician for LASIK. I have been his patient for many years and we both felt the time was right for me to have the surgery." - Tracie Max Sachs, 5x World CupChampion Speed Skier, LASIK Patient

"I have had no problems, I see perfectly and I wish I had done this years agoDr. Coad is the best!!" - Mario Cantone, Actor, LASIK Patient

Read More Testimonials...

Read the rest here:
Chelsea Eye Ophthalmology, PLLC - LASIK Surgeon & LASIK ...

Your child's ability to see the world depends on healthy eyes. At Children's National Health System, our pediatric ophthalmologists are experts at diagnosing and treating complex eye problems, congenital disorders and rare eye conditions, such as strabismus, childhood cataract and glaucoma. We offer comprehensive care for patients of all ages, from newborns to young adults.

Not all eye doctors are the same. Eye conditions that threaten your child's sight, such as retinopathy of prematurity, require the expertise of a well-trained and experienced pediatric ophthalmologist.

Our team includes board-certified ophthalmologists with advanced fellowship training who specialize in pediatric care. Our pediatric ophthalmologists are trained to recognize and manage eye diseases and disorders in children whose vision is still developing.

Features of our ophthalmology program include:

Every year, our ophthalmology team treats thousands of children and adults with strabismus or misalignment of the eyes. That high volume allows us to develop expertise, not only in the common problems such as crossing (esotropia) and wandering (exotropia) of the eyes, but also in the most complex cases, such as:

Each type of strabismus requires a different approach, and so does every patient. We use the results of a comprehensive eye exam and orthoptics evaluation to develop a personalized treatment specific to your child's age and diagnosis.

Surgery may be the best treatment option for some patients, with or without eyeglasses or patching. We take into account factors such as the type and severity of the strabismus and your child's age when making a recommendation. We will sit down and discuss the potential risks and benefits of surgery with you, so you can make the most informed choice. We schedule most evaluations and surgery on an outpatient basis.

We emphasize a multidisciplinary approach to care. That means, our program includes a team of experts specialized in all aspects of eye care so we can provide the most comprehensive care possible.

Learn more:

At Children's National, we use the most advanced equipment and techniques for accurate diagnostic tests and screenings. A comprehensive eye evaluation takes about two hours. Your ophthalmologist may order one or several of the following tests:

For more information or to schedule an appointment, please call 202-476-3015.

Read more here:
Ophthalmology | Children's National

Lahey Hospital & Medical Centers Department of Ophthalmology serves the needs of patients by providing comprehensive medical care. We seek to foster an environment of high caliber professionalism in order to exceed our patients expectations.

A team of more than 70 medical professionals provides a full range of eye care. Nearly 20 ophthalmology and optometry specialists work in proximity to each other, allowing interchange of talent. Examination rooms are adjacent to the operating suite to facilitate care.

In addition to providing routine eye examinations, staff diagnose and treat all aspects of eye disease in adolescents, adults and seniors. These include cataracts, glaucoma, cornea and external disease, laser vision correction, trauma, low vision, retinal and vitreous disease, oculoplastics and neuro-ophthalmology.

Patient undergoing an eye exam.The Department of Ophthalmology provides comprehensive eye care and complete medical and surgical treatment. The foundation of the department is an experienced, highly motivated staff whose mission has multiple goals:

Dr. Edward Connolly, who joined Lahey in 1969, and Dr. Joseph Bowlds, who joined in 1972, founded Ophthalmology Services at the then Lahey Clinic. The department was initially located on Commonwealth Avenue in Boston. Over the next 14 years, optometrists and ophthalmologists were hired.

By 1994, when the department was located in Burlington, it consisted of six full-time ophthalmologists, one part-time ophthalmologist, and five full-time optometrists. Today, the departments unique multidisciplinary approach to patient care involving the collaboration of ophthalmology and optometry specialists with different areas of expertise allows for cross-fertilization of talent, producing the very best in comprehensive patient care.

The Eye Institute, a dynamic eye care center housed within the Department of Ophthalmology, was conceived in the summer of 1994 as part of the re-engineering of the ophthalmology program, led by F. Denton Wertz III, MD, then the chair of the department. After opening at Lahey Medical Center, Peabody the Institutes comprehensive approach to vision care and medical and surgical diseases of the eyes made it popular with patients. In addition to providing state-of-the-art diagnostic capabilities in all areas of vision care, it is situated adjacent to the operating suite, facilitating the very best in care.

Ophthalmology services are also available through Lahey at its Arlington site, located at the former Symmes Hospital. In addition, a program providing subspecialized ophthalmology care for patients in Bermuda is currently under development.

Continue reading here:
Ophthalmology - lahey.org

What is ophthalmology?Ophthalmology is a branch of medicine which deals with the eyes and visual system, and diagnosing, treating, and preventing diseases and conditions affecting them.Ophthalmology is a mixed medical and surgical specialty, and deals with a diverse range of issues. Eye health services are very important, as eye problems, such as cataracts, are very common, affecting a large number of people across the UK, and as the population ages, the incidence of age-related macular degeneration (AMD) increases. If these diseases are caught early enough, they can be treated and managed with the expertise of ophthalmologists.What conditions does an ophthalmologist treat?Although the eye is a small organ, its importance cannot be overstated, and, due to the complexity of our visual mechanics, the eyes can be affected by a number of different problems and diseases. As such, ophthalmologists have to be trained to deal with a wide variety of visual problems. Some of these eye problems are very common for instance, cataract surgery is the second most common operation performed on the NHS in England.Some of the conditions ophthalmologists treat include:Which subspecialties are included under ophthalmology?Sub-specialty interests for ophthalmologists include:

See original here:
The best Ophthalmologists in 2019 | TopDoctors

If you are experiencing an eye emergency involving sudden vision loss or the acute onset of pain or double vision, call 911 or seek emergency care immediately. The UK Chandler Emergency Department has ophthalmology providers on call 24/7.

UK Advanced Eye Care provides expert eye care for all ages ranging from simple eye exams to diagnosing and treating the most complex eye diseases in a new state-of-the art facility.

Using the widest range and most up-to-date technology in the state, our fellowship-trained specialists are able to diagnose and treat various eye diseases and conditions including:

Having our entire team of optometrists, general ophthalmologists and specialists together in one location allows for improved efficiency, increased continuity of care, and ease of referrals for further testing, surgical consultation or treatment.

At UK Advanced Eye Care, we are proud of our patient care services. We are hiring full-time ophthalmic technicians and patient care coordinators. We offer competitive benefits and on-the-job training.

Contact Philip Moss if you are interested: 859-323-0729 or philip.moss@uky.edu.

Shriners Hospitals for Children Medical Center Lexington

110 Conn TerraceFourth and Fifth FloorsLexington, KY 40508

(Primary eye care and all subspecialty eye care)

UK HealthCare - Turfland

2195 Harrodsburg RoadFirst floorLexington, KY 40504

Monday - Friday: 8:00 am-5:00 pm

(Primary eye care)

PLEASE NOTE: UK Optical Shops at Shriners and Turfland are CLOSED. The providers of General Ophthalmology are still seeing patients as scheduled. See full notice

UK HealthCare Jessamine Eye Center

100 John Sutherland DriveSuite 3Nicholasville, KY 40356

UK Manchester Eye Care

231 White St.Manchester, KY 40962

(Primary eye care, retina and vitreous disorders)

UK HealthCare Eye Center - Richmond

920 Barnes Mills RoadSuite DRichmond, KY 40475

(Cornea and external diseases, glaucoma, pediatric ophthalmology, primary eye care, retina and vitreous disorders)

UK HealthCare - Baptist Health

1760 Nicholasville RoadSuite 203Lexington, KY 40503

(Corneal and external diseases, primary eye care, retina and vitreous disorders)

More here:
Advanced Eye Care | UK HealthCare